Cytotoxic T Lymphocytes in Treating Patients with Malignancies with BK and/or JC Virus

Inclusion Criteria

• Patients >= 2 years and =< 80 years of age. English and non-English speaking patients are eligible
• Immunocompromised patients; and/or non-immunocompromised patients with polyomavirus (PML)/JC virus encephalitis; and/or patients with any type of malignancies; and/or HIV/AIDs; and/or history of solid organ transplant; and/or Merkel polyoma-virus related Merkel cell tumor(s) with measurable disease on imaging per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
• Patients with microscopic hematuria OR biopsy proven BK nephritis and urine or blood polymerase chain reaction (PCR) positive for BK virus and/or JC viral encephalitis and/or JC end-organ disease and/or polyomavirus
• Clinical status at enrollment to allow tapering of steroids to less than 0.5 mg/kg/day of prednisone
• Patients who are currently receiving treatment with cidofovir, leflunomide, or other antiviral therapy with no response, will be eligible for CTL infusion
• Written informed consent and/or signed assent from patient, parent or guardian. Patients with cognitive impairments are eligible
• Negative pregnancy test in female patients of childbearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization; women of child bearing potential must be willing to use an effective contraceptive measure while on study
• Patients enrolled on this study may be enrolled on other investigational new drug (IND) studies at the discretion of the principal investigator (PI)

Exclusion Criteria

• Patients receiving prednisone > 0.5 mg/kg/day at time of enrollment, or have received anti-thymocyte globulin (ATG) within 14 days or have received donor lymphocyte infusion (DLI) or Campath within 28 days of enrollment
• Patients with other uncontrolled infections (except HIV/AIDS); for bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment; for fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment; progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection; persisting fever without other signs or symptoms will not be interpreted as progressing infection
• Patients with active acute graft-versus-host disease (GVHD) grades II-IV